ATX-GD-59
Immune In trials Human trials
A mix of two short peptides copied from the thyroid-stimulating hormone receptor. The idea is to retrain the immune system to tolerate that receptor, so it stops making the antibodies that drive Graves' disease, instead of suppressing immunity overall.
Evidence at a glance
- Evidence
- Human trials — Studied in people
- Status
- Reached clinical trials
- Dosing
- No human study has set a dose
One small open-label study in 12 people; no control group.
What studies report
- Fell antibody levels against the thyroid receptor in most participants of a small phase 1 study
How it works
Two short fragments of the TSH receptor given to retrain immune tolerance. Presenting the target antigen in this form is meant to stop the immune system attacking the thyroid, rather than suppressing immunity generally.
Where it acts
ThymusThe library groups this compound under Immune. The diagram shows that target, not every tissue it reaches.
Illustrated
AI-generated subject illustration; not a depiction of the compound or evidence of its effects.
Why people take it
Reasons people seek it out — not a list of proven effects.
Status: Early (phase 1) human study only. Not approved.
- Route
- Subcutaneous injection, from reconstituted lyophilised powder
- Available as
- 1.6 mg
Search PubMed for ATX-GD-59 → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.